In a multicenter cooperative study, an enzyme immunoassay (EIA) using purified antigen of lymphadenopathy-associated virus was compared with radioimmune precipitation (RIP) for detection of antibody to human immunodeficiency virus (HIV) in 634 patients with acquired immunodeficiency syndrome or related conditions, 687 apparently healthy persons at risk for HIV infection, 93 controls with cancer or autoimmune diseases, and 10,038 blood or plasma donors. Excluding the donors, the EIA was reactive in 875 (61.9%) of 1,414 subjects; compared with RIP, the sensitivity and specificity of EIA both were 99.8%. There was one false-positive EIA among 148 intravenous drug abusers and two false-negative EIAs among 472 apparently healthy homosexual men; no other discordant results between EIA and RIP occurred in these subjects. The EIA was repeatably reactive in 20 donors (0.2%), among whom 13 (65%) were positive by RIP; none of 529 randomly selected EIA-negative donors was RIP positive. In addition to its utility as a screening test in low-risk populations, the EIA for antibody to lymphadenopathy-associated virus is useful as a diagnostic test in persons with clinical evidence of or at risk for HIV infection.
The discovery of the retrovirus(es) associated with acquired immune deficiency syndrome (AIDS) was a signal advance in the potential control of the syndrome. The first two isolates were termed lymphadenopathy-associated virus (LAV) (2) and human T-cell lymphotropic virus type III (8) , but it is now clear that these and other similar viruses (10) are closely related to one another (10, 11, 13, 15 [477] [478] [479] [480] [481] [482] [483] [484] 1986 ) and is used in this paper as a generic term for all of these agents; LAV and human T-cell lymphotropic virus type III designate the specific prototype isolates.
Identification of HIV led rapidly to the development of enzyme immunoassays (EIA) for the detection of antibody to the virus and to evidence that the majority of seropositive persons harbor HIV (6) . These assays were promptly applied to screening of potential blood donors to prevent transmission of infection via blood and blood products. The early EIAs were designed to maximize sensitivity at the potential sacrifice of specificity. In addition, the ability of EIA to detect antibody to specific viral antigens, as determined by Western blotting or radioimmune precipitation (RIP), has been challenged, as has the ability of EIA to predict the presence of HIV itself in persons with clinical diagnosis of AIDS or related conditions (9) . Reduced specificity of these assays has been shown to be due in part to contamination of HIV antigen preparations with class Il human leukocyte antigens present in the H-9 cell line used to grow the virus (17, J.B. Hunter and J. E. Menitove, Letter, Lancet ii:397, 1985; P. Kuhnl, S. Seidl, and G. Holzberger, Letter, Lancet i: [1222] [1223] 1985) . Accordingly, the early EIAs were initially approved by the U.S. Food and Drug Administration for screening low-prevalence populations but not for diagnostic use in persons suspected of being infected with HIV.
We developed an EIA for antibody to HIV based on isolation and purification of antigen from LAV grown in the CEM cell line, which lacks class II human leukocyte antigens (12 (5) . Demographic and behavioral data on these subjects were not collected.
Subjects with clinical evidence of HIV infection and those in populations at risk for AIDS gave written informed consent to participate in the present study or, in some cases, had previously given written consent for the use of stored serum samples for subsequent experimental assays. The AIM patients and volunteer blood donors gave specific informed consent to participate in this study. Specimens from paid plasma donors were salvaged from the collection center before being discarded, without identifying information. The study was approved by the institutional review boards of all cooperating institutions. Laboratory methods. (i) EIA. All specimens were tested by the LAV EIA (Genetic Systems Corp., Seattle, Wash.) per manufacturer instructions using microtiter plates with wells coated with purified LAV antigen grown in the CEM cell line (7). In summary, a 100-pl sample of a 1:401 dilution of serum or plasma was added to each well. After incubation at 37°C for 1 h, the wells were washed, 100 ,ul of horseradish peroxidase-labeled goat anti-human immunoglobulin was added to each well, and the plates were reincubated at 37°C for 1 h. After repeat washing, 100 pil of a tetramethylbenzidine chromogen solution was added to each well; after 30 min of incubation in the dark at room temperature, 100 ,ul of 3 N H2SO4 was added to terminate the chromogenic reaction. A450 was measured with a 630-nm reference filter in an automatic microplate reader (Genetic Systems Corp.).
For each microtiter plate, a cutoff optical density (OD) value was determined by adding 0.225 to the mean of three negative controls assayed on the same plate. To standardize comparisons of OD values between plates, the ratio of the specimen OD to the cutoff OD for the controls for each plate was used for such comparisons. By definition, therefore, an OD ratio of .1.0 represented a reactive result. Initially negative results were considered definitive. Initially reactive specimens were rediluted and retested in duplicate with a new cutoff value determined for the new plate; only those specimens with at least one reactive repeat test were considered positive.
(ii) Confirmatory assays. RIP assays were performed by a previously described method (14) , and Western blot assays were carried out as described by Towbin et al. (16) . RIP and Western blot test results were interpreted by a modification of the U.S. Food and Drug Administration criteria for the Western blot assay (6). Specifically, positivity was defined by antibody to antigen gp4l (with or without antibody to other antigens) or by antibody to p25 plus antibody to pi8, p34, p55, p68, gpllO, or gpl50. All other patterns of reactivity were considered negative.
Study design. The initial and repeated EIAs were performed in the cooperating investigators' laboratories. The EIA was repeated once again in our laboratory (Genetic Systems Corp.) if there was a discrepancy between the EIA result obtained by the investigator and the RIP assay. Except where specifically indicated, only the investigator's EIA result was used in analyzing the data. RIP assays were carried out in our laboratory (Genetic Systems Corp.) on all specimens from all study groups except the blood and plasma donors. For the blood and plasma donors, RIP assays were performed on all initially or repeatably EIAreactive specimens and on a computer-generated random sample of 529 EIA-negative specimens, including a minimum of 100 specimens from each donation center. Western blot assays were performed in the Genetic Systems Corp. laboratory on all specimens with discrepancies between EIA and RIP results. All RIP and Western blot assays were carried out and interpreted by personnel who were blind to all prior test results and to the reason for conducting a confirmatory assay.
Statistical Specimens from a total of 10 subjects gave discrepant EIA and RIP results ( Fig. 3 . Six of these sera (five of the seven included in Fig. 3 However, as illustrated in Fig. 1 phenomenon might be due to atypical reactivity to HIV or infection with one or more related retroviruses (or other agents), or it may have other explanations. In the absence of a definitive means to exclude HIV infection, LAV EIAseropositive persons with similar atypically reactive RIP or Western blotting results should continue to be deferred as blood or tissue donors. Studies that might help to elucidate the interpretation of such results include analysis of serial serum samples from persons with recent acquisition of HIV, virus cultures and perhaps antigen detection assays, studies of patients infected with other retroviruses, and detailed analysis of the patterns of antigen-specific antibody reactivity in larger numbers of patients.
In summary, the LAV EIA is useful for screening low-risk populations such as prospective donors of blood, plasma, tissues, or organs and as a diagnostic assay for HIV infection in patients with clinical evidence of HIV infection and persons at risk for HIV infection. Repeatably reactive specimens from persons at low risk for HIV infection should be retested with a presumptively specific assay, but confirmatory tests are rarely necessary in those with clinical evidence of or at substantial risk for HIV infection.
